The U.S. Food and Drug Administration warned Thursday that AbbVie Inc.’s hepatitis C treatments Viekira Pak and Technivie could cause serious liver harm among patients with underlying liver disease.
from WSJ.com: US Business http://ift.tt/1LITV0h
via IFTTT
No comments:
Post a Comment